This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : CRISPR Therapeutics AG Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 09:20 AM
CRISPR Therapeutics Names Naimish Patel as Chief Medical Officer; Promotes Julianne Bruno to Chief Operating Officer MT
CRISPR Therapeutics Announces Executive Changes CI
Transcript : CRISPR Therapeutics AG Presents at Bank of America Health Care Conference 2024, May-15-2024 09:20 AM
Oppenheimer Adjusts CRISPR Therapeutics Price Target to $95 From $102, Maintains Outperform Rating MT
Barclays Adjusts Price Target on CRISPR Therapeutics to $67 From $80, Maintains Equal-Weight Rating MT
Needham Adjusts Price Target on CRISPR Therapeutics to $88 From $90, Keeps Buy Rating MT
Baird Adjusts Price Target on CRISPR Therapeutics to $52 From $46, Keeps Neutral Rating MT
CRISPR Therapeutics AG Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Earnings Flash (CRSP) CRISPR THERAPEUTICS AG Reports Q1 Revenue $504,000 MT
CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing in Vivo Gene Editing Approach CI
Citigroup Adjusts CRISPR Therapeutics' Price Target to $89 From $88, Keeps Buy Rating MT
Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing MT
Mizuho Adjusts Price Target on CRISPR Therapeutics to $99 From $82, Maintains Buy Rating MT
Morgan Stanley Adjusts Price Target on CRISPR Therapeutics to $48 From $46, Maintains Underweight Rating MT
Wells Fargo Raises Price Target on CRISPR Therapeutics to $70 From $55, Maintains Equal-Weight Rating MT
Barclays Raises Price Target on CRISPR Therapeutics to $80 From $61, Maintains Equal-Weight Rating MT
Chardan Ups Price Target on CRISPR Therapeutics to $112 From $110, Keeps Buy Rating MT
RBC Raises Price Target on CRISPR Therapeutics to $66 From $57 on Strengthened Balance Sheet, Casgevy Approval; Sector Perform, Speculative Risk Kept MT
Transcript : CRISPR Therapeutics AG Presents at Citi 2024 Virtual Oncology Leadership Summit, Feb-21-2024 10:00 AM
Needham Adjusts CRISPR Therapeutics' Price Target to $90 From $88, Keeps Buy Rating MT
CRISPR Therapeutics Swings to Q4 Profit, Revenue Increases MT
CRISPR Therapeutics AG Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (CRSP) CRISPR THERAPEUTICS AG Reports Q4 Revenue $201.2M MT
Earnings Flash (CRSP) CRISPR THERAPEUTICS AG Posts Q4 EPS $1.10 MT
Chart CRISPR Therapeutics AG
More charts
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
65.26 USD
Average target price
86.57 USD
Spread / Average Target
+32.65%
Consensus
  1. Stock Market
  2. Equities
  3. CRSP Stock
  4. News CRISPR Therapeutics AG
  5. CRISPR Therapeutics Names Naimish Patel as Chief Medical Officer; Promotes Julianne Bruno to Chief Operating Officer